Suchergebnisse - "Curtin, Nicola"

PubPharm (228)

101

1-Substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones Endowed with Dual DNA-PK/PI3-K Inhibitory Activity

enthalten in: Journal of medicinal chemistry | 2013

von Cano, C. | Saravanan, K. | Bailey, C. | +14

102

Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer

enthalten in: Molecular cancer therapeutics | 2013

von Batey, M. | Zhao, Y. | Kyle, S. | +6

103

Visualization of a DNA-PK/PARP1 complex

enthalten in: Nucleic acids research | 2013

von Spagnolo, L. | Barbeau, J. | Curtin, N. | +2

104

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

enthalten in: Journal of the National Cancer Institute | 2013

von Drew, Y. | Mulligan, E. | Vong, W. | +9

105

Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361

enthalten in: Journal of the National Cancer Institute | 2013

von Calabrese, C. | Almassy, R. | Barton, S. | +18

106

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

enthalten in: Cancer chemotherapy and pharmacology | 2013

von Plummer, R. | Lorigan, P. | Steven, N. | +10

107

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

enthalten in: Cancer chemotherapy and pharmacology | 2013

von Plummer, R. | Lorigan, P. | Steven, N. | +10

108

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

enthalten in: Cancer chemotherapy and pharmacology | 2013

von Plummer, R. | Lorigan, P. | Steven, N. | +10

109

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

enthalten in: Cancer chemotherapy and pharmacology | 2013

von Plummer, R. | Lorigan, P. | Steven, N. | +10

110

DNA repair dysregulation from cancer driver to therapeutic target

enthalten in: Nature reviews. Cancer | 2012

von Curtin, N.